United States to buy 100 million doses of Covid-19 vaccine from Moderna


The United States government has signed an agreement with Moderna to purchase 100 million doses of its potential Covid-19 vaccine, mRNA-1273.

As agreed, the United States will pay up to $ 1.525 billion for the manufacture and delivery of the vaccine doses, including incentive payments for timely delivery.

The deal also includes an option to purchase 400 million additional doses of mRNA-1273.

MRNA-1273 is an mRNA vaccine against Covid-19 jointly developed by Moderna and researchers at the National Institute of Allergy and Infectious Disease (NIAID) Vaccine Research Center.

Covid-19 Report – Updated twice a week
Understand the Covid-19 epidemic, its economic impact and its implications for specific sectors

Get the free report

Our parent business intelligence company

.covid-banner ->

In May, the United States Food and Drug Administration (FDA) granted the mRNA-1273 Fast Track designation.

Currently, it is one of the few candidate vaccines to move to the final stage of testing. The phase III study began last month and recruitment is expected to end in September.

Moderna CEO Stéphane Bancel said, “We appreciate the confidence of the US government in our mRNA vaccine platform and the continued support.

“We are advancing the clinical development of mRNA-1273 with the ongoing Phase III study conducted in collaboration with NIAID and BARDA.

“At the same time, we are increasing our manufacturing capacity with our strategic partners, Lonza, Catalent and Rovi, to face this global health emergency with a safe and effective vaccine.”

In recent weeks, the US government has stepped up efforts to procure millions of doses of potential Covid-19 vaccines from various companies as part of the Operation Warp Speed ​​program.

US Secretary of Health and Human Services Alex Azar said: “For Operation Warp Speed, we are assembling a large portfolio of vaccines to increase the chances of having at least one safe and effective vaccine by the end of this year. .

“With this latest investment, we will have supported the vaccine candidate developed by Moderna in partnership with the NIH, from early development to clinical trials and now to manufacturing, with the potential to deliver millions of safe and effective doses to the American people. ”

Last month, Moderna signed an agreement to receive an additional $ 472 million to support advanced clinical development of mRNA-1273.


Please enter your comment!
Please enter your name here